Use of colistin in the treatment of multiple-drug-resistant gram-negative infections
Use of colistin in the treatment of multiple-drug-resistant gram-negative infections
复制标题
DOI：
10.1093/ajhp/62.1.39
复制
发表时间：
2005-01-01
影响因子：
2.7
通讯作者：
Jódar, R
中科院分区：
文献类型：
--
作者：
Berlana, D;Llop, JM;Jódar, R
目的.研究了粘菌素用于治疗多重耐药（MDR）革兰氏阴性微生物引起的感染。在西班牙住院成人患者中研究了粘菌素治疗MDR革兰氏阴性微生物引起的感染的疗效和肾毒性的发生。纳入2001年1月至2001年10月期间接受治疗的患者。在研究期间，71个疗程的吸入性粘菌素，12个疗程的静脉注射或肌内（i.m.）80例患者鞘内注射粘菌素12个疗程。所有患者均感染MDR微生物：69例（86%）感染鲍曼不动杆菌，11例（14%）感染铜绿假单胞菌。41例（51%）患者的发作由A.鲍曼不动杆菌只对粘菌素敏感。在获得治疗后重复标本的患者中，92%的致病微生物被清除。住院死亡率为18%（14例患者）。在接受i.v.或i.m.治疗的患者中，平均血清尿素或肌酐浓度无显著变化。therapy.Conclusion. 80例A.鲍曼不动杆菌或铜绿假单胞菌，并且似乎是有效和安全的。
Purpose. The use of colistin for the treatment of infections caused by multiple drug-resistant (MDR) gram-negative-microorganisms was studied.Methods. The efficacy of colistin for treating infections caused by MDR gram-negative microorganisms, and the development of renal toxicity were studied in hospitalized adult patients in Spain. Patients treated between January 2001 and October 2001 were included.Results. Over the study period, 71 courses of inhaled colistin, 12 courses of i.v. or intramuscular (i.m.) colistin, and 12 courses of intrathecal colistin were administered to 80 patients. All were infected by MDR organisms: 69 (86%) by Acinetobacter baumannii and 11 (14%) by Pseudomonas aeruginosa. In 41 patients (51%), the episodes were caused by A. baumannii strains exclusively to colistin. The causative organisms were cleared in 92% of the patients from whom posttreatment repeat specimens were obtained. The in-hospital mortality rate was 18% (14 patients). There were no significant changes in mean serum urea or creatinine concentrations in patients receiving i.v. or i.m. therapy.Conclusion. Colistin was used in 80 patients, infected with A. baumannii or P. aeruginosa and appeared to be efficacious and safe.